Lv1
46 积分 2024-09-09 加入
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
11小时前
待确认
The First Triple Agonist for Antiobesity: Retatrutide
7天前
已完结
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
10天前
已完结
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
1个月前
已完结
The efficacy and safety of liraglutide
3个月前
已完结
Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A
3个月前
已完结
Nutrition Support among Critically Ill Children with AKI
3个月前
已关闭
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
4个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
4个月前
已完结
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP‐1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study
4个月前
已完结
皖公网安备34019202002308
